The discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies. There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases. Nevertheless, large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.
- Anti-vascular endothelial growth factor therapy
- Pegaptanib sodium
ASJC Scopus subject areas
Research output: Contribution to journal › Article
TY - JOUR
T1 - Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
AU - Ciulla, Thomas A.
AU - Rosenfeld, Philip J
PY - 2009/5/1
Y1 - 2009/5/1
N2 - Lippincott Williams & Wilkins.
AB - Lippincott Williams & Wilkins.
KW - Anti-vascular endothelial growth factor therapy
KW - Bevacizumab
KW - Neovascularization
KW - Pegaptanib sodium
KW - Ranibizumab
UR - http://www.scopus.com/inward/record.url?scp=65549136672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65549136672&partnerID=8YFLogxK
U2 - 10.1097/ICU.0b013e328329d173
DO - 10.1097/ICU.0b013e328329d173
M3 - Article
C2 - 19381089
AN - SCOPUS:65549136672
VL - 20
SP - 166
EP - 174
JO - Current Opinion in Ophthalmology
JF - Current Opinion in Ophthalmology
SN - 1040-8738
IS - 3